Search alternatives:
significant use » significant cause (Expand Search), significant i.e (Expand Search), significantly used (Expand Search)
mean decrease » a decrease (Expand Search)
non decrease » nn decrease (Expand Search), point decrease (Expand Search), note decreased (Expand Search)
use based » rule based (Expand Search), case based (Expand Search), one based (Expand Search)
Showing 141 - 160 results of 134,500 for search '(( significant use based ) OR ( significant ((non decrease) OR (mean decrease)) ))', query time: 2.97s Refine Results
  1. 141
    <i>In vitro</i> 95% CI lower and upper mean susceptibility responses of field isolates to antimalarials.

    <i>In vitro</i> 95% CI lower and upper mean susceptibility responses of field isolates to antimalarials. by Winnie Okore (14139712)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  2. 142
    PBMT parameters.

    PBMT parameters. by Katayoon Montazeri (18389243)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  3. 143
    Table_1_High-Intensity Use of Smartphone Can Significantly Increase the Diagnostic Rate and Severity of Dry Eye.XLS

    Table_1_High-Intensity Use of Smartphone Can Significantly Increase the Diagnostic Rate and Severity of Dry Eye.XLS by Chunyang Wang (500547)

    Published 2022
    “…Non-invasive keratograph tear meniscus height(NIKTMH) decreased significantly compared to the baseline level, while the proportion of NIKTMH<0.20 mm increased significantly. …”
    Save to List
    Saved in:
  4. 144
    Sociodemographic characteristics of the participants.

    Sociodemographic characteristics of the participants. by Daniel Waiganjo Kinyanjui (15877725)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  5. 145
    Summary of BFI traits as described by Sattler and Schunck.

    Summary of BFI traits as described by Sattler and Schunck. by Daniel Waiganjo Kinyanjui (15877725)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  6. 146
    Decreased clonogenic capacity of U87MG and U251MG GB cells following treatment with SHG-44 and cis-platin at equal concentrations.

    Decreased clonogenic capacity of U87MG and U251MG GB cells following treatment with SHG-44 and cis-platin at equal concentrations. by Denis Mustafov (19137870)

    Published 2025
    “…Microscopic images were captured at ×40 magnification. Data represent mean values ± standard deviation, n = 3. <b>Legends:</b> ns: non-significant, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.…”
    Save to List
    Saved in:
  7. 147
    Map of Zimbabwe highlighting the districts detected as persistent hotspots of <i>S. haematobium</i> prevalence (PPHS), persistent hotspots of decreased praziquantel efficacy (EPHS), and districts of both PPHS and EPHS.

    Map of Zimbabwe highlighting the districts detected as persistent hotspots of <i>S. haematobium</i> prevalence (PPHS), persistent hotspots of decreased praziquantel efficacy (EPHS)... by Takafira Mduluza (39754)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 148
    IRE1 depletion decreases heterochromatin, DNA and H3K9me3 methylation, and UHRF1.

    IRE1 depletion decreases heterochromatin, DNA and H3K9me3 methylation, and UHRF1. by Iratxe Zuazo-Gaztelu (21071939)

    Published 2025
    Save to List
    Saved in:
  9. 149
    Decreased thrombin activity levels in PAR KO following 24 hours following ischemia.

    Decreased thrombin activity levels in PAR KO following 24 hours following ischemia. by Efrat Shavit-Stein (3186678)

    Published 2021
    “…<p>(A) Total thrombin activity is significantly decreased in PAR1 KO compared to WT mice (t-test). …”
    Save to List
    Saved in:
  10. 150
    The framework of model parameter estimation based on GLUE and different combinations of observed data in this work.

    The framework of model parameter estimation based on GLUE and different combinations of observed data in this work. by Yonghui Zhang (279832)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  11. 151
    Decreasing phagocytosis did not block NRF2 activation in <i>Lgy</i> infection.

    Decreasing phagocytosis did not block NRF2 activation in <i>Lgy</i> infection. by Marta Reverte (10450927)

    Published 2021
    Save to List
    Saved in:
  12. 152
    S4 NIRS data for control and S4 NIRS data for rTMS.

    S4 NIRS data for control and S4 NIRS data for rTMS. by Nakako Okamoto (18501452)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  13. 153
    Experimental procedure.

    Experimental procedure. by Nakako Okamoto (18501452)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  14. 154
    Summary of post-treatment disease course measures from MDMA-AT publications.

    Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 155
    Study selection criteria.

    Study selection criteria. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 156
    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.

    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 157
    Disease course measures after the PTSD treatments.

    Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 158
    PICOS criteria for the SLR.

    PICOS criteria for the SLR. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 159
    Summary of post-treatment CAPS score changes from MDMA-AT publications.

    Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 160
    Summary of post-treatment disease course measures from off-label medications clinical trials.

    Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: